SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-23-209009
Filing Date
2023-08-10
Accepted
2023-08-10 16:02:38
Documents
52
Period of Report
2023-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q d447610d10q.htm   iXBRL 10-Q 1075898
2 EX-10.4 d447610dex104.htm EX-10.4 113969
3 EX-31.1 d447610dex311.htm EX-31.1 10273
4 EX-31.2 d447610dex312.htm EX-31.2 10278
5 EX-32.1 d447610dex321.htm EX-32.1 5054
  Complete submission text file 0001193125-23-209009.txt   5111922

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA cbay-20230630.xsd EX-101.SCH 40626
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE cbay-20230630_cal.xml EX-101.CAL 26680
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE cbay-20230630_def.xml EX-101.DEF 175855
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE cbay-20230630_lab.xml EX-101.LAB 300332
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cbay-20230630_pre.xml EX-101.PRE 233909
46 EXTRACTED XBRL INSTANCE DOCUMENT d447610d10q_htm.xml XML 805211
Mailing Address 7575 GATEWAY BOULEVARD SUITE 110 NEWARK CA 94560
Business Address 7575 GATEWAY BOULEVARD SUITE 110 NEWARK CA 94560 510-293-8800
CymaBay Therapeutics, Inc. (Filer) CIK: 0001042074 (see all company filings)

IRS No.: 943103561 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36500 | Film No.: 231159170
SIC: 2834 Pharmaceutical Preparations